Parkinson Disease Neuroprotection Clinical Trial: Clinical Centers

描述（由申请人提供）：NINDS寻求建立临床试验站点，这些站点将在神经保护治疗的新方法的开发和测试中进行协作和合作。佛蒙特大学医学院（UVM/COM）的神经病学项目、达特茅斯希区柯克医学中心（DHMC）和缅因州神经病学中心（缅因州医学中心）将共同努力建立一个新英格兰北部临床试验中心（NNE-CTC）。具体来说，NNE-CTC的目的是：招募和随访早期帕金森病（PD）患者，进行PD神经保护的随机临床试验；提供高质量的临床评估，数据输入和管理，并满足实验性神经治疗的所有监管法规；在中心结构和整个项目允许的范围内，发展新的介入治疗方法和评估策略；将我们的临床中心完全整合到NINDS赞助的神经保护试验项目的运作中，并充分配合试验的各个方面。除了这些具体目标之外，NNE-CTC的总体目标是为新英格兰北部和纽约州北部的公民带来参与神经退行性疾病不断发展的治疗方法的机会。

DESCRIPTION (provided by applicant): The NINDS seeks to establish Clinical Trial Sites that will collaborate and cooperate in the development and testing of new approaches to neuroprotection therapy. The Neurology programs at the University of Vermont College of Medicine (UVM/COM), the Dartmouth Hitchcock Medical Center (DHMC), and Maine Neurology (Maine Medical Center) will work together in order to establish a Northern New England Clinical Trials Center (NNE-CTC). Specifically, the aims of the NNE-CTC are:To recruit and follow subjects with early Parkinson's disease (PD) for a randomized clinical trial of Neuroprotection in PD;To provide high quality clinical assessment, and data entry and management, and to meet all regulatory statutes outlined for experimental neurotherapeutics;To evolve new approaches to interventional therapy and assessment strategies as permitted within the structure of the Center and overall project;To fully integrate our Clinical Center into the operation of the NINDS sponsored Neuroprotection Trial program and to fully cooperate with all aspects of the trial.In addition to these specific aims, an overall goal of the NNE-CTC is to bring opportunities for the citizens of Northern New England and Upstate New York to participate in the evolving therapies for neurodegenerative disorders.